Redwood City, CA – August 2, 2023 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023.

•Achieved record worldwide revenue of $17.2 million in the second quarter of 2023, a 23% increase over the same period last year

•Delivered a new high of $11.0 million in U.S. revenue in the second quarter of 2023, representing 28% year-over-year growth

•Realized gross margin of 74% in the second quarter of 2023

•Added 15 new U.S. treatment centers for Zephyr Valves in the second quarter 2023

“Our team delivered record results globally as hospitals increased their screening and treatment of emphysema patients with Zephyr Valves,” said Glen French, President, and Chief Executive Officer. “We expect to continue to grow adoption and expand our global treatable market as we seek to meet the substantial unmet clinical needs of patients with severe emphysema.”

Total worldwide revenue in the second quarter of 2023 was $17.2 million, a 23% increase from $14.0 million in the second quarter of 2022. U.S. revenue was $11.0 million, a 28% increase from the second quarter of 2022. International revenue was $6.2 million, a 16% increase compared to the second quarter of 2022. The growth in revenue reflects continued commercial momentum and adoption of Zephyr Valve procedures.

Gross profit in the second quarter of 2023 was $12.7 million, compared to $10.4 million for the second quarter of 2022. Gross margin for the second quarter of 2023 was 74%, compared to 75% for the same period in 2022, reflecting slightly lowered capacity utilization.

Operating expenses in the second quarter of 2023 were $29.2 million, compared to $24.8 million for the second quarter of 2022, representing an increase of 17%. The increase in operating expenses was primarily attributable to an increase in clinical and development costs related to our AeriSeal program, increases in selling and legal expenses, and higher stock -based compensation expense.

Net loss in the second quarter of 2023 was $16.2 million, or $0.43 per share, compared to a net loss of $14.6 million, or $0.40 per share, for the same period in 2022.

Adjusted EBITDA loss in the second quarter of 2023 was $10.3 million compared to $9.8 million for the same period in 2022.

Cash, cash equivalents, and marketable securities totaled $147.6 million as of June 30, 2023.

Pulmonx is increasing its expectation for revenue in 2023 to now range from $64 million to $66 million, which represents approximately 19% to 23% growth over the Company's fiscal year 2022 revenue. This updated guidance compares to prior 2023 revenue guidance of $63 million to $65 million.

The Company continues to expect gross margin for the full year 2023 to fall within the range of 73% to 74%.

Pulmonx also continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based compensation.

Pulmonx will host a conference call today, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter financial results. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.

To supplement Pulmonx’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx’s business.

Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management's financial and operational decision-making, including evaluation of Pulmonx’s historical operating results.

The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance.

Reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is set forth in the tables below.

The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of non-GAAP measures may differ from similarly titled measures used by others.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our commercial strategy to grow the adoption of our Zephyr Valve treatment and expand our global treatable market, our expectations regarding account activity and productivity, our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, profitability, guidance for full year 2023, commercial momentum, physician engagement and awareness of the benefits of the Zephyr Valve, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including the Quarterly Report on Form 10-Q filed with the SEC on May 8, 2023, available at www.sec.gov.

Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Brian Johnston

Gilmartin Group

investors@pulmonx.com